Inherited Metabolic Disorders of the Liver

Chapter

Abstract

Inherited metabolic disorders (IMD) include more than 70 monogenetic disorders that are mostly associated with enzyme deficiencies. Although IMDs are rarely diagnosed, their combined incidence among full-term neonates has been estimated to account for 20 % of illnesses. One of the most common IMDs originating in the liver and necessitating transplantation is α1-antitrypsin deficiency. Although several in vitro and in vivo models have been used to study this disease, the application of patient-specific hIPSCs and their differentiation to hepatic lineages has allowed not only physiologically relevant insights into the disease mechanisms but also provides the opportunity to understand patient-patient variabilities in phenotypes and sets the stage for the identification of novel biomarkers and the design of drugs that target them. This chapter discusses the wide application range of hIPSCs and addresses how this cellular system can meet previous shortcomings in advancing research into the molecular mechanisms of disease.

Keywords

Liver disease Cirrhosis hIPSC-derived hepatocytes Alpha-1-antitrypsin deficiency 

7.1 Introduction: Inherited Metabolic Disorders of the Liver

The liver is a unique and vital organ by the broad spectrum of its functions. It processes consumed substances and sustains reserves of iron, vitamins, and minerals. It detoxifies alcohol, drugs, and other chemicals and removes inhaled poisons such as exhaust or smoke, all of which accumulate in the bloodstream. The liver is also the site of synthesis of plasma proteins such as albumin, blood clotting factors, hormones, as well as bile required for the digestion of lipids. Finally, the liver has an essential metabolic activity by storing glycogen. Most of these activities are managed by one cell type, the hepatocyte, which constitutes the main cellular unit of the liver (Kmieć 2001). Genetic mutations targeting any gene involved in the functioning of hepatocytes can destroy the capacity of the liver to carry out these essential activities, thereby threatening the life of the afflicted patient.

Genetic diseases associated with impaired liver function are combined under the umbrella term “inherited metabolic disorders” (IMDs) which was originally coined “inborn errors of metabolism” by the British physician Archibald Garrod (1923). This class of heterogeneous diseases includes almost 70 disorders that are characterized primarily by defects in single, enzyme-coding genes that lead to lack of enzymatic activity and toxic substrate accumulation (Martins 1999). While individual events of IMDs are relatively rare, taken together they account for an incidence of 1 in 2,500–5,000 among full-term neonates (Seymour et al. 1997). Most of these disorders require medical treatment, which needs to be employed immediately after birth to avoid interference with early mental and physical development. IMDs that compromise vital liver functions are generally targeted with orthotopic liver transplantation (OLT) since only a healthy donor liver can restore the missing metabolic function. However, this intervention is associated with drawbacks since it implies high risk of surgical complications, indefinite immunosuppression associated with severe side effects, and potential organ rejection. Furthermore, the number of organ donors has remained constant during the past 10 years, while the demand for liver transplantation has more than doubled in the meantime. This situation is anticipated to worsen in the foreseeable future due to the hepatitis C pandemic and increase in cirrhosis associated with obesity. The development of alternative therapies to OLT has therefore become a major objective in the field of regenerative medicine. Further goals for the translational research community include the advancement of physiologically relevant cell models to study the underlying disease mechanisms of the respective disorders and the design and screening of novel drug compounds.

7.2 An Example: α1-Antitrypsin Deficiency

α1-antitrypsin (A1AT) deficiency is one of the most common IMDs, affecting 1 in 2000 individuals of North Caucasian decent (Sveger 1976). A1AT deficiency is characterized by a point mutation in the A1AT gene (SERPINA1), which is primarily expressed and synthesized by hepatocytes and secreted as a circulating plasma glycoprotein. While wild-type A1AT acts as an antiprotease that enzymatically inhibits overactive neutrophil elastase in pulmonary tissues, defective A1AT protein synthesis results in intracellular A1AT protein polymerization, accumulation and reduced A1AT levels in the circulation and in target organ tissues such as the lungs. A1AT deficiency is inherited as an autosomal codominant trait leading to homozygous or heterozygous phenotypes. Homozygous A1AT-deficient individuals are at an increased risk of developing chronic hepatitis, liver cirrhosis, and chronic-obstructive respiratory disease. This chapter introduces the pathophysiology of A1AT deficiency and explains the suitability of human-induced pluripotent stem cells (hIPSCs) to study this disease and unearth unknown mechanisms involved in its pathogenesis.

7.2.1 α1-Antitrypsin

A1AT is a 52 kDa acute phase glycoprotein synthesized mainly in the liver but at low levels is also locally produced by blood monocytes, tissue macrophages, and other non-hepatic tissues, such as airway epithelial cells (Carlson et al. 1988; Perlmutter et al. 1985). Secreted into the blood stream, A1AT functions as the most abundant circulating protease inhibitor in man, acting in all organ tissues but most prominently in the lung (Morrison et al. 1984). As member of the serine protease inhibitor (serpin) superfamily, A1AT serves to prevent pulmonary tissue damage from overactive proteases, particularly human neutrophil elastase (Travis and Salvesen 1983). Neutrophil elastases are active in several inflammatory and degenerative diseases (Jenne 1994). They are stored alongside other serine proteases (e.g., cathepsin G) in azurophil granules of neutrophils and cause hydrolytic, proteolytic, and oxidative breakdown of phagocytosed compounds (e.g., bacteria and viruses) (Sandborg and Smolen 1988). However, lysosomal enzymes may escape from activated neutrophils and digest connective tissue matrix proteins (e.g., elastin) (Janoff and Scherer 1968). To prevent this, the pulmonary environment is generally bathed in excess A1AT and supports A1AT molecules to form specific complexes with free proteases. This inactivates the enzyme through conformational deformation and is achieved through the spatial arrangement of A1AT’s single β-sheet A, nine α-helices, and a mobile reactive-center loop peptide that all create a pseudo-substrate for neutrophil elastase (Eriksson 1996; Huntington et al. 2000). Following binding, the cleaved reactive-center loop peptide inactivates bound neutrophil elastase by inserting into A1AT’s central β-sheet A (Huntington et al. 2000) (Fig. 7.1, left panel). In the event of imbalances between neutrophil elastase and A1AT levels, as observed in A1AT deficiency, the reduction of inhibitory activity from A1AT can lead to protease-induced destruction of pulmonary connective tissue (Janoff 1985) which may manifest as emphysema (Tobin et al. 1983).
Fig. 7.1

Conformational changes and differences in function between wild-type and mutant α1-antitrypsin protein variants. Wild-type SERPINA1 sequences result in native protein folding of α1-antitrypsin (A1AT) protein and secretion into the circulation where upon A1AT’s reactive-center loop binding to neutrophil elastase, it is cleaved and inserted into A1AT’s β-sheet A, resulting in enzymatic inactivation of neutrophil elastase. Mutations in SERPINA1 undermine this process and lead to instable A1AT intermediates that readily polymerize (Structural protein images were reproduced with permission from Dr. Bibek Gooptu (Gooptu and Lomas 2008))

7.2.2 Genetic Basis, Molecular Mechanisms, and Epidemiology

Although more than 120 allelic variants of A1AT have been discovered to date, only a minority of those have been linked with pathological A1AT deficiency (Brantly et al. 1988; DeMeo and Silverman 2004). The most prevalent A1AT variants in white ethic populations are PiM (~95 %), PiS (2–3 %), and PiZ (1–3 %) alleles (Luisetti and Seersholm 2004). While the M allele annotates wild-type A1AT, the S and Z allele signify deficient A1AT variants caused by point mutations in SERPINA1 (Jeppsson 1976; Owen and Carrell 1976). The most common and severe form of clinically diagnosed A1AT deficiency is linked to the Z allele, which is dependent on a point mutation-induced amino acid substitution of a lysine for a glutamic acid residue in SERPINA1’s exon 5 (Glu342Lys) (Jeppsson 1976). The most supported mechanism for the polymerization of its protein product has been linked to mutant Z A1AT’s conformational instability and termed “loop-sheet” polymerization (Lomas et al. 1992). It describes the widening of A1AT’s β-sheet A as a result of the amino acid substitution at position 342 and the subsequent insertion of the reactive-center loop of another A1AT polypeptide into the opened β-sheet A, resulting in irreversible linkage of two Z A1AT molecules (Lomas et al. 1992) (Fig. 7.1, right panel). While the M A1AT allele contributes to 50 % of the overall serum A1AT levels, the Z allele supplies only ~5 % to circulating A1AT plasma concentrations (Fregonese and Stolk 2008). As a result, homozygous PiZZ patients are characterized by plasma A1AT deficiency levels of ~10–15 %. The remaining synthesized A1AT is prevented from secretion through intracellular degradation (~70 %) and accumulation (~15 %) of polymers that can be detected as polymer filaments with electron microscopy or as intrahepatic endoplasmic reticulum (ER) inclusions (Lomas et al. 1992) (Fig. 7.2). The Z allele is most prevalent in Northern European countries, where 0.10 % are affected by Z-related-deficient allele combinations (PiSZ, PiZZ) (Luisetti and Seersholm 2004; Sveger 1976; Serres 2002). Worldwide there are 3.4 million individuals with pathological allele deficiencies (PiSS, PiSZ, PiZZ) (Serres 2002; American Thoracic Society and European Respiratory 2003).
Fig. 7.2

Intracellular processing of mutant α1-antitrypsin protein. The synthesis and translocation of mutant Z α1-antitrypsin (A1AT) protein into the endoplasmic reticulum (ER) lumen results in formation of soluble monomeric protein units, which may further assemble to form insoluble polymer aggregates. With the help of chaperones, a minority of mutant A1AT monomers attain native folding and will be processed in the Golgi apparatus for secretion. Terminally misfolded A1AT proteins are bound by BiP and retro-translocated from the ER to the cytosol for subsequent ubiquitination and proteasomal degradation (ERAD). Insoluble A1AT polymer aggregates are removed from hepatic ER through autophagy, which eliminates protein aggregates, damaged ER, and other organelles via lysosomal degradation pathways. Due to the continued synthesis of mutant Z A1AT, these disposal pathways can become overwhelmed and fail to resolve ER stress inferred by protein accumulation. As a result, affected cells display signs of inflammation and intracellular injury and may trigger apoptotic pathways

7.2.3 Clinical Symptoms

The significant reduction of secreted A1AT is caused by pathogenic accumulation of A1AT in the liver of homozygous PiZZ individuals (Laurell and Eriksson 1963). This leads to toxic gain-of-function mechanisms in hepatocytes and marks A1AT deficiency as the most common genetic liver disease affecting children and requiring juvenile liver transplantation (Gartner Jr et al. 1984). A1AT deficiency can present as neonatal cholestasis (jaundice), juvenile hepatitis, enlarged spleen, and swelling of the abdomen during the first months or years of life. 10–15 % of A1AT-deficient children and 40–60 % of overall PiZZ patients will develop chronic liver disease at some stage, which may advance to liver cirrhosis or liver cancer (Sveger 1976, 1988; Eriksson et al. 1986).

Similar to lung disease, there is great variability between A1AT-deficient patients in the phenotypic expression of associated liver disease. The onset, progression, and severity of liver disease have been shown to vary widely even between PiZZ siblings (Hinds et al. 2006). Generally, higher rates of degradation of misfolded intracellular A1AT polymers have been linked with reduced liver disease burden (Wu et al. 1994). As such, mechanisms to upregulate autophagy have been tied to reduced A1AT polymer concentrations and less liver injury in a mouse model (Kaushal et al. 2010). To date, the only curative intervention for end-stage A1AT deficiency is whole-organ liver transplantation (Fairbanks and Tavill 2008). The overall mortality of individuals with severe A1AT deficiency has been examined in several studies and has been reported between 18 and 37 % (Larsson 1978; Seersholm et al. 1994; Stoller et al. 2005).

Until recently, the detailed molecular mechanisms causing Z A1AT polymer accumulation in the ER lumen of hepatocytes to trigger liver disease were not well understood. Improved insights into these processes would improve the understanding of what distinguishes the A1AT-deficient subpopulation susceptible to liver disease (~20 %) from those protected (~80 %) (Fairbanks and Tavill 2008). Given that the mere Glu342Lys amino acid substitution in SERPINA1 cannot account for the emergence of liver disease, PiZZ individuals without liver disease likely carry certain genetic traits that protect from A1AT polymer-associated disease. Alternatively, PiZZ individuals with liver disease may be exposed to environmental factors or carry a specific genetic deposition that renders them susceptible to disease. Several groups have attributed the buildup of A1AT aggregates and resultant liver injury to impaired and delayed degradation of Z A1AT (Wu et al. 1994). This may be due to compromised interactions between Z A1AT and factors of the calnexin/calreticulin cycle, which generally aid glycoproteins in their folding and tag permanently misfolded glycoproteins for proteasomal degradation (Cameron et al. 2009; Qu et al. 1996). Besides impaired proteasomal degradation of Z A1AT molecules, elimination of A1AT polymers via autophagy may also be reduced, delayed, or overwhelmed (Perlmutter 2011). Other studies have shown that A1AT polymer accumulation activates the NF-kB pathway independent of the unfolded protein response (UPR), triggering toxic ER stress signals in protein-overloaded hepatocytes (Hidvegi et al. 2005; Ordóñez et al. 2013). The absence of the UPR may prevent downstream pathways from eliminating misfolded proteins and appropriately regulate apoptosis under chronic ER stress (Hidvegi et al. 2005). It also has been proposed that A1AT polymer-bearing hepatocytes cannot recognize the ordered structures of A1AT polymers as misfolded proteins and therefore fail to mount strong protein disposal pathways (Graham et al. 1990; Hidvegi et al. 2005).

7.3 In Vitro and In Vivo Models: How to Study α1-Antitrypsin Deficiency

As outlined in the previous sections, A1AT deficiency is a liver disease with substantial health consequences but limited options for treatment. In the past, the pressing need to gain insights into the underlying disease mechanisms and the development of new therapeutic tools has been hampered by limited availability and viability of primary A1AT-deficient and wild-type hepatocytes to study the disease. Although animal models have contributed to improved understanding of A1AT deficiency, physiological variability between animal and man has questioned the extrapolation of findings into a Homo sapiens context. The advent of human-induced pluripotent stem cells (hIPSCs) derived from patients with A1AT deficiency and their differentiation to the hepatic lineage has generated cells which phenocopy the disease phenotypes and can target these aforementioned obstacles (Rashid et al. 2010). This section discusses the use and shortcomings of alternative A1AT deficiency models and how hIPSC-derived hepatocytes have developed into a suitable platform for investigating the pathophysiology of A1AT deficiency.

7.3.1 Primary PiZZ Hepatocytes

Primary hepatocytes isolated from PiZZ patients are the most appropriate cell model to study A1AT deficiency. However, it requires invasive biopsies to access the liver tissue. Furthermore, multiple groups have failed to extract and plate high-quality PiZZ hepatocytes from cirrhotic liver tissue which can become available during liver transplantations (Gramignoli et al. 2013). At this stage of disease severity, PiZZ hepatocytes are generally incorporated into a highly fibrotic tissue and are therefore very difficult to isolate, let alone culture (Bhogal et al. 2011). At earlier stages of disease when the liver is still pre-fibrotic, isolation of PiZZ hepatocytes through enzymatic digestion of liver explant tissue may be more feasible. However, oftentimes PiZZ patients are asymptomatic and therefore remain undiagnosed at that point, making it difficult to obtain biological material. Furthermore, due to the absence of long-term culture systems for primary hepatocytes, the study of disease progression over time cannot be accomplished. Finally, the dissociation of hepatocytes from their niche liver microenvironment and subsequent plating in 2D conditions is well known to cause loss of hepatic functionality in primary hepatocytes (Bhatia et al. 2014; Gramignoli et al. 2013).

7.3.2 Evaluation of Alternative Models to Study α1-Antitrypsin Deficiency

In the past, several in vitro and in vivo models have aided in advancing the A1AT deficiency field. For example, cloning of human PiM A1AT into the murine germ line generated transgenic mice that expressed human A1AT levels in serum and liver (Carlson et al. 1988; Sifers et al. 1987). Using the same technique, Carlson et al. and others generated transgenic mice expressing the human PiZ A1AT gene product. These animals exhibited mutant A1AT synthesis and showed retention of mutant A1AT in hepatic ER, hepatocellular damage, and chronic liver injury that correlated with the level of hepatic PiZ A1AT accumulation. The phenotypes in pups resembled human neonatal hepatitis (Carlson et al. 1989; Dycaico et al. 1988). Despite the significant increase in inflammation recorded in these transgenic PiZ mice, there was no statistically significant increase in fibrosis. This was attributed to the faster metabolism and shorter life expectancy of mouse versus man, which may not suffice for the development of chronic disease, including fibrosis, cirrhosis, and hepatocellular carcinoma.

In order to evaluate the pathogenic impact of an elastase to antielastase imbalance on pulmonary health, the pallid mouse has been used to study A1AT deficiency (Martorana et al. 1993). This mouse strain suffers from hereditary emphysema and develops pulmonary lesions comparable with human emphysema. While the hepatic A1AT activity is not disrupted in this mouse model, circulating A1AT levels are reduced and exhibit a diminished capacity for elastase inhibition. Despite the suitability of studying the pallid mouse for its reduced serum elastase inhibitory effects and resultant lung tissue damage, it cannot provide insight into the underlying mechanisms of hepatic disease in PiZZ A1AT humans (Martorana et al. 1993).

Several other yeast and mammalian cell line models have also been shown to recapitulate features of A1AT deficiency (Gosai et al. 2010; Wu et al. 1994; Ordóñez et al. 2013; Cabezn et al. 1984; Kruse et al. 2006; McCracken and Brodsky 1996; Scott et al. 2007; Werner et al. 1996). Despite the exciting findings obtained from these studies, the lack of physiological human A1AT expression makes it difficult to draw conclusions into the pathogenesis of A1AT deficiency. Multiple A1AT gene copy numbers, interference of endogenous animal antiproteases, a genetic background that may not permit onset of disease upon A1AT polymer accumulation, and the absence of endogenous promoters and transcription factors to activate A1AT expression all contribute to a likely non-physiological system to study A1AT deficiency. Furthermore, differences in tissue composition, anatomy, physiology, lack of conservation of gene order, and the animal’s inbred genetic background can direct SERPINA1 mutations to phenotypes that may not faithfully phenocopy the clinical picture of human A1AT deficiency (Shapiro 2007). For instance, instead of a single gene, as observed in primates, murine SERPINA1 exists as a small gene family of up to five genes that synthesize several isoforms (Borriello and Krauter 1991). It still remains to be determined which member/s of this gene cluster correspond to the functional equivalent of human A1AT (Barbour et al. 2002).

7.4 Modeling α1-Antitrypsin Deficiency Using Human-Induced Pluripotent Stem Cells

7.4.1 Human-Induced Pluripotent Stem Cells

hIPSCs, derived from patients with specific disease backgrounds and their subsequent differentiation to specialized somatic cells in which the disease manifests, have emerged as in vitro systems to model various diseases ex vivo. The derivation of hIPSCs followed shortly after the very first induced pluripotent stem cell lines were generated from mouse embryonic fibroblasts (Takahashi et al. 2007; Takahashi and Yamanaka 2006). This was achieved through forced expression of transcription factors c-Myc, Oct3/4, Sox2, and Klf-4 (Yamanaka factors) in fibroblasts. While this process of direct reprogramming was previously performed with viral vectors, several techniques are now available that use non-integrative methods to safely deliver the reprogramming factors (e.g., episomal vectors) (Yu et al. 2011). hIPSCs resemble embryonic stem cells (pluripotent stem cells derived from an embryo at the blastocyst stage) in terms of their expression of pluripotent genes, DNA methylation patterns, doubling time, formation of embryoid bodies, teratoma formation, and viable chimeras, as well as their potency for self-renewal and differentiation into almost any cell type (Wernig et al. 2007). hIPSC research and the development of differentiation protocols to generate specific cell types have promised to yield great advancements for the disease modeling field but also for developmental biology, personalized cell-based therapy, and the generation of platforms to develop and screen new pharmaceuticals (Rashid and Vallier 2010). In the field of transplantation and regenerative medicine, the possibility to produce and implant personalized hIPSC-derived somatic cells into patients removes the risk of tissue rejection inherent to allogeneic transplants, high costs associated with invasive transplantation, and lifelong administration of immunosuppressive drugs and bypasses some of the ethical issues associated with embryonic stem cells.

7.4.2 Derivation and Hepatic Differentiation of α1-Antitrypsin-Deficient hIPSC

In the search for human cellular systems that closely mimic human A1AT-deficient hepatocyte dysfunction, our group and others have generated hIPSC lines from PiZZ patients and developed hepatic differentiation protocols to direct hIPSCs along their in vivo developmental path to form hepatocyte-like cells (A1AT-ZZ) (Rashid et al. 2010; Tafaleng et al. 2015; Wilson et al. 2015) (Fig. 7.3). This was achieved by culturing hIPSCs in changing cytokine combinations and concentrations (e.g., FGF2, activin A, BMP4, Wnt, OSM, and HGF), as well as media compositions that mimic the microenvironment during hepatic embryogenesis in vivo (Si-Tayeb et al. 2010; Touboul et al. 2010). This process includes the transition from pluripotency to definitive endoderm and its subsequent anteriorization (foregut); specification into hepatic endoderm, which develops cells into bipotential hepatocytes; and finally hepatic maturation to generate hepatocytes. The classification of hIPSC-derived cells as “hepatocytes” (or “hepatocyte-like cells”) is based on their ability to recapitulate key features of their in vivo equivalents. This includes co-expression of hepatic genes (e.g., HNF4α, A1AT), hepatic protein synthesis, and secretion (e.g., transthyretin, albumin), as well as liver-specific functionalities such as metabolic enzyme activity (cytochrome P450) and liver engraftment in animal models of acute liver failure (Rashid et al. 2010; Hengstler et al. 2005; Schwartz et al. 2014). Importantly, hepatocyte-like cells generally still feature low expression of hepatic maturity markers when compared to primary hepatocytes (Sampaziotis et al. 2015). Since low maturity of hIPSC-derived hepatocytes is a shared shortcoming of other differentiation protocols, many groups are currently focused on advancing this field (e.g., Huang et al. 2009).
Fig. 7.3

Modeling α1-antitrypsin deficiency using hIPSC-derived hepatocytes. Fibroblasts from a PiZZ α1-antitrypsin-deficient individual were reprogrammed to generate human-induced pluripotent stem cells (hIPSCs). While this cell line carried the disease-specific SERPINA1 mutation, corrective genome-editing techniques resulted in an isogenic wild-type hIPSC line. Both cell lines differentiated to hepatic lineage allow for comparative disease modeling of α1-antitrypsin deficiency

In addition, A1AT-ZZs exhibited all disease-specific characteristics of A1AT deficiency, including A1AT polymer formation, intracellular retention in the hepatic ER, and reduced A1AT secretion (Rashid et al. 2010; Tafaleng et al. 2015; Wilson et al. 2015). Thus, A1AT-ZZ hepatocyte-like cells represent an attractive system to study the molecular mechanisms directing the disease pathophysiology.

7.5 Applications of α1-Antitrypsin-Deficient hIPSC-Derived Hepatocytes

7.5.1 Cell Therapy: Genetic Correction of Diseased hIPSCs to Generate Wild-Type hIPSC

In order to generate a wild-type cell line, our group employed zinc finger nucleases and piggyBac-based genome-editing techniques to correct the SERPINA1 mutation in hIPSCs responsible for A1AT deficiency, creating an otherwise isogenic wild-type hIPSC line (Yusa et al. 2011). This cell line was termed A1AT-RR, referring to the corrected SERPINA1 gene. Once differentiated to hepatic lineages, the disease phenotype was rescued in this cell type and A1AT-RRs exhibited normal levels of A1AT secretion as well as the absence of intracellular A1AT polymer formation or accumulation (Yusa et al. 2011). The resulting wild-type hIPSC-derived hepatocytes were transplanted successfully into animal models for liver failure, providing a first proof of principle that hIPSCs could be used for personalized medicine of inherited metabolic diseases (Yusa et al. 2011). With increased hepatic maturity, we anticipate that transplantation of these cells will be able to correct hepatic functionality.

7.5.2 Disease Modeling: Linking Hepatic Accumulation of α1-Antitrypsin Polymers to Pathological Liver Conditions

Despite the volume of information available about the intracellular polymerization of A1AT, it has been unclear how the A1AT polymer retention leads to liver disease. Due to the capacity of A1AT-deficient hIPSC-derived hepatocytes to be cultured long-term, it is possible to observe the accumulation of A1AT polymers over time. Studies aimed at investigating the functional divergences between diseased and healthy hepatocytes can utilize A1AT-ZZs and A1AT-RRs, which only differ in the absence or presence of the SERPINA1 mutation. This allows for detailed comparisons of genetic and protein material at modeled end-stage liver disease, circumventing the interference of differing genetic backgrounds. Using this cellular platform, we have been able to dissect potential pathways involved in linking polymer accumulation and liver disease and allowed us to detect novel biomarkers for this disease (Segeritz et al. in preparation). Interestingly, recent genome-wide studies have also revealed novel aspects of the disease including UPR activity early during the process of hepatocyte specification (Wilson et al. 2015). Thus, these data which would have been impossible to obtain in any other model system suggest that liver disease associated with A1AT could be induced during early liver development.

7.5.3 Patient-Patient Variability: Differentiating the Susceptible from the Protected

hIPSC-derived hepatocytes derived from A1AT-deficient patients have also aided in addressing the question of why some affected individuals are protected from acquiring liver disease, while others suffer from cirrhotic livers that require liver transplantation. The derivation of hIPSCs from A1AT-deficient patients with and without disease and their differentiation to hepatocyte-like cells has allowed insights into the individual disease phenotypes (Tafaleng et al. 2015). While the intracellular Z A1AT in hIPSC-derived hepatocytes of patients without liver disease was primarily degraded by autophagic pathways, elimination of Z A1AT was delayed in hIPSC-derived hepatocytes of patients that suffered from liver disease. Z A1AT in the latter group also appeared to accumulate in ER inclusions. This work suggested that the observed variation in liver disease phenotypes of A1AT deficiency is linked to the rate of misfolded A1AT degradation. This opens the door for the development and testing of specific drug targets that control proteostasis and enhance intracellular degradation such as carbamazepine (Hidvegi et al. 2010). Furthermore, these observations also indicate that hIPSC-derived hepatocytes can be used to predict disease progression and susceptibility, allowing for the implementation of personalized therapeutics.

7.5.4 Drug Development and Drug Screening: Finding a Cure for α1-Antitrypsin Deficiency

Due to the current absence of therapies for the treatment of A1AT deficiency, there is great urgency to develop and test new drug compounds in human systems. hIPSCs derived from A1AT-deficient individuals and differentiated to hepatocytes could act as a suitable platform to screen efficacy of novel drug compounds. Previously, hIPSC-derived hepatocytes have been employed in drug toxicity studies and to show patient-specific sensitivity to a given drug compound (Cayo et al. 2012; Takayama et al. 2013). However, for the first time, a recent separate study has shown that carbamazepine could improve autophagic flux in A1AT-ZZ hepatocyte-like cells (Wilson et al. 2015), thereby reinforcing the interest of clinical trial currently testing this small molecule for A1AT deficiency. Considered together these results exemplify how patient-specific, hIPSC-derived hepatocytes could be used to screen drug compounds to reverse or prevent the accumulation of A1AT polymers.

7.6 Conclusion

Using the example of A1AT deficiency as a representative IMD, this chapter has demonstrated the suitability of patient-specific hIPSC to model metabolic disorders affecting the liver. Indeed, hIPSCs derived from patient with specific IMDs can be easily differentiated into somatic cell types in which the disease manifests to address questions pertinent to the disease mechanism, the variability in disease phenotypes, and the development of treatment regimens. Thus, hIPSC-based hepatocyte platforms represent a physiologically relevant system to gain new understandings of IMDs and design strategies to reduce the burden of these diseases.

References

  1. American Thoracic Society and European Respiratory (2003) American Thoracic Society Documents American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with. Am J Respir Clin Care Med 168:818–900. doi:10.1164/rccm.168.7.818 CrossRefGoogle Scholar
  2. Barbour KW, Wei F, Brannan C, Flotte TR, Baumann H, Berger FG (2002) The murine alpha-1-proteinase inhibitor gene family: polymorphism, chromosomal location, and structure. Genomics 80(5):515–522. doi:10.1006/geno.2002.6864 CrossRefPubMedGoogle Scholar
  3. Bhatia SN, Underhill GH, Zaret KS, Fox IJ (2014) Cell and tissue engineering for liver disease. Sci Transl Med 6(245):1–21Google Scholar
  4. Bhogal RH, Hodson J, Bartlett DC, Weston CJ, Curbishley SM, Haughton E, Williams KT et al (2011) Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. PLoS One 6(3):1–8. doi:10.1371/journal.pone.0018222 CrossRefGoogle Scholar
  5. Borriello F, Krauter KS (1991) Multiple murine alpha-1-protease inhibitor genes show unusual evolutionary divergence. Proc Natl Acad Sci 88:9417–9421CrossRefPubMedPubMedCentralGoogle Scholar
  6. Brantly M, Nukiwa T, Crystal RG (1988) Molecular basis of alpha-1-antitrypsin deficiency. Am J Med 84(6A):13–31CrossRefPubMedGoogle Scholar
  7. Cabezn T, Wilde MDE, Heriont P, Loriaut R, Bollent A (1984) Expression of human a1-antitrypsin cDNA in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 81:6594–6598CrossRefGoogle Scholar
  8. Cameron PH, Chevet E, Thomas DY, John JM, Cameron PH, Chevet E, Pluquet O et al (2009) Calnexin phosphorylation attenuates the release of partially misfolded alpha-1-antitrypsin to the secretory pathway. J Biol Chem 284:34570–34579. doi:10.1074/jbc.M109.053165 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Carlson JA, Rogers BB, Sifers RN, Hawkins HK, Finegold MJ, Woo SL (1988) Multiple tissues express alpha 1-antitrypsin in transgenic mice and man. J Clin Invest 82(1):26–36CrossRefPubMedPubMedCentralGoogle Scholar
  10. Carlson JA, Rogers BB, Sifers RN, Finegold MJ, Clift SM, DeMayo FJ, Bullock DW et al (1989) Accumulation of iZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest 83(4):1183–1190CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cayo MA, Cai J, Delaforest A, Noto FK, Nagaoka M, Clark BS, Collery RF et al (2012) JD induced pluripotent stem cell–derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 56(6):2163–2171. doi:10.1002/hep.25871 CrossRefPubMedPubMedCentralGoogle Scholar
  12. DeMeo DL, Silverman EK (2004) Alpha-1-antitrypsin deficiency. 2: genetic aspects of alpha-1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 59:259–264. doi:10.1136/thx.2003.006502 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Dycaico MJ, Grant SGN, Felts K, Nichols WS, Geller SA, Hager JH, Pollard AMYJ et al (1988) Neonatal hepatitis induced by alpha-1-antitrypsin: a transgenic mouse model. Science 242:1409–1412CrossRefPubMedGoogle Scholar
  14. Eriksson S (1996) A 30-year perspective on alpha-1-antitrypsin deficiency. Chest 110(6):237–242CrossRefGoogle Scholar
  15. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. N Engl J Med 314:736–739CrossRefPubMedGoogle Scholar
  16. Fairbanks KD, Tavill AS (2008) Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 103(8):2136–2141. doi:10.1111/j.1572-0241.2008.01955.x; quiz 2142CrossRefPubMedGoogle Scholar
  17. Fregonese L, Stolk J (2008) Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 3(16):1–9. doi:10.1186/1750-1172-3-16 Google Scholar
  18. Garrod AE (1923) Inborn errors of metabolism, vol 2. Henry Frowde and Hodder & Stoughton, LondonGoogle Scholar
  19. Gartner JC Jr, Zitelli BJ, Malatack JJ, Shaw BW, Iwatsuki S, Starzl TE (1984) Orthotopic liver transplantation in children: two-year experience with 47 patients. Pediatrics 74(1):140–145PubMedPubMedCentralGoogle Scholar
  20. Gooptu B, Lomas DA (2008) Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 205(7):1529–1534. doi:10.1084/jem.20072080 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Gosai SJ, Kwak JH, Luke CJ, Long OS, King DE, Kovatch KJ, Paul A, et al (2010) Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin a1-antitrypsin Z. PLoS One 5(11):e15460. doi:10.1371/journal.pone.0015460
  22. Graham K, Le A, Sifers R (1990) Accumulation of the insoluble PiZ variant of human alpha 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP. J Biol Chem 265:20463–20468PubMedGoogle Scholar
  23. Gramignoli R, Tahan V, Dorko K, Skvorak KJ, Hansel MC, Zhao W, Venkataramanan R et al (2013) New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res 11(1):563–573. doi:10.1016/j.scr.2013.03.002.New CrossRefPubMedPubMedCentralGoogle Scholar
  24. Hengstler J, Brulport M, Schormann W, Bauer A, Hermes M, Nussler A, Fandrich F et al (2005) Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol 1(1):61–74CrossRefPubMedGoogle Scholar
  25. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH, Hidvegi T, Schmidt BZ, Hale P et al (2005) Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NF-KB, and BAP31 but not the unfolded protein response. J Biol Chem 280:39002–39015. doi:10.1074/jbc.M508652200 CrossRefPubMedGoogle Scholar
  26. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N et al (2010) An autophagy-enhancing drug promotes degradation of mutant alpha-1-antitrypsin Z and reduces hepatic fibrosis. Science 329:229–232. doi:10.1126/science.1190354 CrossRefPubMedGoogle Scholar
  27. Hinds R, Hadchouel A, Shanmugham NP, Al-Hussaini A, Chambers S, Cheeseman P, Mieli-Vergani G et al (2006) Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease. J Pediatr Gastroenterol Nutr 43:136–138CrossRefPubMedGoogle Scholar
  28. Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, Cen J et al (2009) Article direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Stem Cell 14(3):370–384. doi:10.1016/j.stem.2014.01.003. Elsevier IncGoogle Scholar
  29. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923–926CrossRefPubMedGoogle Scholar
  30. Janoff A (1985) Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 132(2):417–433PubMedGoogle Scholar
  31. Janoff A, Scherer J (1968) Mediators of inflammation in leukocyte lysosomes – IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. J Exp Med 128(5):1137–1155CrossRefPubMedPubMedCentralGoogle Scholar
  32. Jenne DE (1994) Structure of the azurocidin, proteinase 3, and neutrophil elastase genes – implications for inflammation and vasculitis. Am J Respir Crit Care Med 150:S147–S154CrossRefPubMedGoogle Scholar
  33. Jeppsson JO (1976) Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ. FEBS Lett 65(2):195–197CrossRefPubMedGoogle Scholar
  34. Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt E, Teckman J (2010) Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med 235(6):700–709. doi:10.1258/ebm.2010.009297.Rapamycin CrossRefGoogle Scholar
  35. Kmieć Z (2001) Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161(III–XIII):1–151Google Scholar
  36. Kruse KB, Brodsky JL, McCracken AA (2006) Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol Biol Cell 17:203–212. doi:10.1091/mbc.E04 CrossRefPubMedPubMedCentralGoogle Scholar
  37. Larsson C (1978) Natural history and life expectancy in severe alpha-1-antitrypsin deficiency, PiZ. Acta Med Scand 204(5):345–351PubMedGoogle Scholar
  38. Laurell CB, Eriksson S (1963) The electrophoretic α 1 -globulin pattern of serum in α 1 -antitrypsin deficiency. Scand J Clin Lab Invest 15(2):132–140. doi:10.3109/15412555.2013.771956 CrossRefGoogle Scholar
  39. Lomas DA, Li-Evans D, Finch JT, Carrell RW (1992) The mechanisms of Z alpha-1-antitrypsin accumulation in the liver. Nature 357:605–607CrossRefPubMedGoogle Scholar
  40. Luisetti M, Seersholm N (2004) Alpha-1-antitrypsin deficiency – 1: epidemiology of alpha-1-antitrypsin deficiency. Thorax 59:164–169CrossRefPubMedPubMedCentralGoogle Scholar
  41. Martins A (1999) Inborn errors of metabolism: a clinical overview. Sao Paulo Med J 117(6):251–265PubMedGoogle Scholar
  42. Martorana PA, Brand T, Gardi C, van Even P, de Santi MM, Calzoni P, Marcolongo P, Lungarella G (1993) The pallid mouse. A model of genetic alpha 1-antitrypsin deficiency. Lab Invest 68(2):233–241. Lab InvestPubMedGoogle Scholar
  43. McCracken AA, Brodsky JL (1996) Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol 132(3):291–298CrossRefPubMedGoogle Scholar
  44. Morrison HM, Afford SC, Stockley RA (1984) Inhibitory capacity of alpha-1-antitrypsin in lung secretions: variability and the effect of drugs. Thorax 39:510–516CrossRefPubMedPubMedCentralGoogle Scholar
  45. Ordóñez A, Snapp EL, Tan L, Miranda E, Marciniak SJ, Lomas DA (2013) Endoplasmic reticulum polymers impair luminal protein mobility and sensitise to cellular stress in α1-antitrypsin deficiency. Hepatology 57(5):2049–2060. doi:10.1002/hep.26173.Endoplasmic
  46. Owen MC, Carrell RW (1976) Alpha-1-antitrypsin: molecular abnormality of S variant. Br Med J 1:130–131CrossRefGoogle Scholar
  47. Perlmutter DH (2011) Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease–associated protein aggregates. Annu Rev Med 62:333–345. doi:10.1146/annurev-med-042409-151920 CrossRefPubMedGoogle Scholar
  48. Perlmutter DH, Cole FS, Kilbridge P, Rossing T (1985) Expression of the alpha-1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci 82:795–799CrossRefPubMedPubMedCentralGoogle Scholar
  49. Qu D, Teckman JH, Omura S, Perlmutter DH (1996) Degradation of a mutant secretory protein, α-1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 271:22791–22795. doi:10.1074/jbc.271.37.22791 CrossRefPubMedGoogle Scholar
  50. Rashid ST, Vallier L (2010) Induced pluripotent stem cells – alchemist's tale or clinical reality? Expert Rev Mol Med 12:25CrossRefPubMedGoogle Scholar
  51. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-doran I et al (2010) Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 120(9):3127–3136. doi:10.1172/JCI43122DS1 CrossRefPubMedPubMedCentralGoogle Scholar
  52. Sampaziotis F, Segeritz C-P, Vallier L (2015) Potential of human induced pluripotent stem cells in studies of liver disease. Hepatology 62(1):303–11CrossRefPubMedGoogle Scholar
  53. Sandborg RR, Smolen JE (1988) Biology of disease: early biochemical events in leukocyte activation. Lab Invest 59:300–320PubMedGoogle Scholar
  54. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN (2014) Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 32(2):504–513. doi:10.1016/j.biotechadv.2014.01.003. Elsevier B.VCrossRefPubMedPubMedCentralGoogle Scholar
  55. Scott CM, Kruse KB, Schmidt Z, Perlmutter DH, Mccracken AA, Brodsky JL (2007) ADD66, a, gene involved in the endoplasmic reticulum-associated degradation of alpha-1-antitrypsin-Z in yeast, facilitates proteasome activity and assembly. Mol Biol Cell 18:3776–3787. doi:10.1091/mbc.E07 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Seersholm N, Kok-jensen A, Dirksen A (1994) Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to non-index cases. Thorax 49:695–698CrossRefPubMedPubMedCentralGoogle Scholar
  57. Serres F (2002) Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency. Chest 122:1818–1829CrossRefPubMedGoogle Scholar
  58. Seymour C, Thomason M, Chalmers R, Addison G, Bain M, Cockburn F, Littlejohns P et al (1997) Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1(11):1–95Google Scholar
  59. Shapiro SD (2007) Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur Respir J 29(2):375–8CrossRefPubMedGoogle Scholar
  60. Sifers RN, Carlson JA, Clift SM, DeMayo FJ, Bullock DW, Woo SL (1987) Tissue specific expression of the human alpha-1-antitrypsin gene in transgenic mice. Nucleic Acids Res 15(4):1459–75CrossRefPubMedPubMedCentralGoogle Scholar
  61. Si-Tayeb K, Lemaigre P, Duncan SA (2010) Organogenesis and development of the liver. Dev Cell 18:175–189. doi:10.1016/j.devcel.2010.01.011 CrossRefPubMedGoogle Scholar
  62. Stoller JK, Tomashefski J, Crystal RG, Arroliga A, Strange C, Killian DK, Schluchter MD et al (2005) Mortality in individuals with severe deficiency of alpha-1-antitrypsin. Chest 127:1196–1204PubMedGoogle Scholar
  63. Sveger T (1976) Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 294:1316–1321CrossRefPubMedGoogle Scholar
  64. Sveger T (1988) The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 77(6):847–851CrossRefPubMedGoogle Scholar
  65. Tafaleng EN, Chakraborty S, Han B, Hale P, Wu W, Soto-gutierrez A, Feghali-bostwick CA et al (2015) Induced pluripotent stem cells model personalized variations in liver disease resulting from a1-antitrypsin deficiency. Hepatology 00(00):1–11. doi:10.1002/hep.27753 Google Scholar
  66. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. doi:10.1016/j.cell.2006.07.024 CrossRefPubMedGoogle Scholar
  67. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. doi:10.1016/j.cell.2007.11.019 CrossRefPubMedGoogle Scholar
  68. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Mizuguchi H (2013) 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34:1781–1789. doi:10.1016/j.biomaterials.2012.11.029. Elsevier LtdCrossRefPubMedGoogle Scholar
  69. Tobin M, Cook P, Hutchison D (1983) Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 77(1):14–27CrossRefPubMedGoogle Scholar
  70. Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S et al (2010) Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 51(5):1754–65CrossRefPubMedGoogle Scholar
  71. Travis J, Salvesen GS (1983) Human plasma proteinase inhibitors. Ann Rev Biochem 52:655–709CrossRefPubMedGoogle Scholar
  72. Werner ED, Brodsky JL, McCracken AA (1996) Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci 93:13797–13801CrossRefPubMedPubMedCentralGoogle Scholar
  73. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151):318–324. doi:10.1038/nature05944 CrossRefPubMedGoogle Scholar
  74. Wilson AA, Ying L, Liesa M, Segeritz C-P, Mills JA, Shen SS, Jean J et al (2015) Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. Stem Cell Rep 4:873–885. doi:10.1016/j.stemcr.2015.02.021 CrossRefGoogle Scholar
  75. Wu Y, Whitman INA, Molmenti E, Moore K, Hippenmeyert P, Perlmutter DH (1994) A lag in intracellular degradation of mutant alpha-1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha-1-antitrypsin deficiency. Proc Natl Acad Sci 91:9014–9018CrossRefPubMedPubMedCentralGoogle Scholar
  76. Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y (2011) Efficient feeder-free episomal reprogramming with small molecules. PLoS One 6(3):1–10. doi:10.1371/journal.pone.0017557 CrossRefGoogle Scholar
  77. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu P-Q, Paschon DE, Miranda E et al (2011) Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478(7369):391–394. doi:10.1038/nature10424 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Wellcome Trust-MRC Stem Cell Institute, Anne McLaren Laboratory, Department of SurgeryUniversity of CambridgeCambridgeUK

Personalised recommendations